Protein conjugation, cross-linking, and PEgylation

Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids

Volumn , Issue , 2004, Pages 119-185

  Hinds, Kenneth D ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056360280     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (229)

1. Bailey, F. E., and Koleske, J. V., Alkylene Oxides and Their Polymers. Marcel Dekker, New York, 1991.
2. Walter, H., Brooks, D. E., and Fisher, D., Partitioning in Aqueous Two-phase Systems. Academic Press, San Diego, 1985.
3. Goding, J. W., Monoclonal Antibodies: Principles and Practice. Academic Press, Orlando, 1986.
4. Zalispky, S., and Harris, J. M., Introduction to chemistry and biological applications of poly(ethylene glycol). In Harris, J. M., and Zalipsky, S. (eds), Polyethylene Glycol Chemistry and Biological Applications, American Chemical Society, Washington, D.C., 1997, p. 1.
5. Jaschke, A., Oligonucleotide-poly(ethylene glycol) conjugates: Synthesis, properties, and applications. In Harris, J. M., and Zalipsky, S. (eds), Polyethylene Glycol Chemistry and Biological Applications, American Chemical Society, Washington, D.C., 1997, p. 265.
6. Duncan, R., and Spreafico, F., Polymer conjugates: pharmacokinetic considerations for design and development. Clinical Pharmacokinetics, 1994; 27: 290.
7. Monfardini, C., and Veronese, F. M., Stabilization of substances in circulation. Bioconjugate Chemistry, 1998; 9: 418.
8. Veronese, F. M., Caliceti, P., and Schiavon, O., New synthetic polymers for enzyme and liposome modification. In Harris, J. M., and Zalipsky, S. (eds), Polyethylene Glycol Chemistry and Biological Applications, American Chemical Society, Washington, D.C., 1997, p. 182.
9. Zalipsky, S., and Lee, C., Use of functionalized polyethylene glycols for modification of polypeptides. In Harris, J. M. (ed), Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications. Plenum Press, New York, 1992.
10. Bailey, F. E., and Koleske, J. V., Poly(Ethylene Oxide). Academic Press, New York, 1976.
11. Lim, K., and Herron, J. N., Molecular simulation of protein-PEG interaction. In: Harris, J. M. (ed.), Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications. Plenum Press, New York, 1992.
12. Gombotz, W. R. et al., Protein adsorption to and elution from polyether surfaces. In: Harris, J. M. (ed.), Polyethylene Glycol Chemistry, Biotechnical and Biomedical Applications. Plenum Press, New York, 1992, p. 247.
13. Ingham, K. C., Protein precipitation with polyethylene glycol. Methods in Enzymology, 1984;104: 351.
14. Abuchowski, A. et al., Alteration of the immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. Journal of Biological Chemistry, 1977; 252: 3578.
15. Working, P. K. et al., Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives. In Harris, J. M., and Zalipsky, S. (eds), Polyethylene Glycol Chemistry and Biological Applications, American Chemical Society, Washington, D.C., 1997, p. 45.
16. Roberts, M. J., Bentley, M. D., and Harris, J. M., Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews, 2002; 54: 459.
17. Fuertges, F., and Abuchowski, A., The clinical efficacy of poly(ethylene glycol)-modified proteins. Journal of Controlled Release, 1990; 11: 139.
18. Herold, D. A., Keil, K., and Bruns, D. E., Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochemical Pharmacology, 1989; 38: 73.
19. Smyth, H. F., Carpenter, C. P., and Weil, C. S., The chronic oral toxicology of the polyethylene glycols. Journal of the American Pharmaceutical Association, 1995; 44: 27.
20. Johnson, A. J., Karpatkin, M. H., and Newman, J., Clinical investigation of intermediate- and high-purity antihaemophilic factor (factor VIII) concentrates. British Journal of Haematology, 1971; 21: 21.
21. Carpenter, C. P. et al., Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicology and Applied Pharmacology, 1971; 18: 35.
22. Shaffer, C. B., and Critchfield, F. H., The absorption and excretion of the solid polyethylene glycols (‘Carbowax compounds’). Journal of the American Pharmaceutical Association, 1947; 36: 152.
23. Yamaoka, T., Tabata, Y., and Ikada, Y., Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration in mice. Journal of Pharmaceutical Sciences, 1994; 83: 601.
24. Richter, A. W., and Akerblom, E., Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. International Archives of Allergy and Applied Immunology, 1983; 70: 124.
25. Richter, A. W., and Akerblom, E., Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergans or placebo, and in healthy blood donors. International Archives of Allergy and Applied Immunology, 1984; 74: 36.
26. Davis, S. et al., Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clinical and Experimental Immunology,1981; 46: 649.
27. Beauchamp, C. O., Dadonna, P. E., and Menapace, D. P., Properties of a novel PEG derivative of calf adenosine deaminase. Advances in Experimental Medicine and Biology, 1984; 165: 47.
28. Levy, Y. et al., Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene-glycol modified adenosine deaminase. Journal of Pediatrics, 1988; 113: 312.
29. Abuchowski, A. et al., Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. Journal of Biological Chemistry, 1977; 252: 3582.
30. Monfardini, C. et al., A branched monomethoxypoly (ethylene glycol) for protein modification. Bioconjugate Chemistry, 1995; 6: 62.
31. Nishimura, H., Matsushima, A., and Inada, Y., Improved modification of yeast uricase with polyethylene glycol accompanied with non-immuno-reactivity towards anti-uricase serum and high enzymatic activity. Enzyme, 1981; 26: 49.
32. Abuchowski, A., Karp, D., and Davis, F. F., Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase. Journal of Pharmacology and Experimental Therapeutics, 1981; 219: 352.
33. Tsuji, J. I., and Hirose, K., Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. International Journal of Immunopharmacology, 1985; 7: 725.
34. Savoca, K. V. et al., Preparation of a non-immunogenic arginase by covalent attachment of polyethylene glycol, Research Communications in Chemistry, Pathology, and Pharmacology, 1978; 29: 113.
35. Sartore, L. et al., Enzyme modification by MPEG with amino acid or peptide as spacer arm. Applied Biochemistry and Biotechnology, 1991; 27: 55.
36. Abuchowski, A., and Davis, F. F., Preparation and properties of polyethylene glycol-trypsin adducts. Biochimica et Biophysica Acta, 1979; 578: 41.
37. Fuke, I., et al. Synthesis of poly(ethylene glycol) derivatives with different branchings and their use for protein modification. Journal of Controlled Release,1994; 30: 27.
38. Chui, H.-C. et al., Enzymatic activity of chymotrypsin and its poly(ethylene glycol) conjugates toward low and high molecular weight substances. Bioconjugate Chemistry, 1993; 4: 290.
39. Wieder, K. J. et al., Some properties of polyethylene glycol:phenylalanine ammonia-lyase adducts. Journal of Biological Chemistry, 1979; 254: 12579.
40. Yoshinaga, K., Shafer, S. G., and Harris, J. M., Effects of polyethylene glycol substitution on enzyme activity. Journal of Bioactive and Compatible Polymers, 1987; 2: 49.
41. Pasta, P., Riva, S., and Carrea, G., Circular dichroism and fluorescence of polyethylene glycol-substilisin in organic solvents. FEBS Letters, 1988; 236: 329.
42. Ashihara, Y. et al., Modification of E. coli asparaginase with polyethylene glycol: disappearance and binding activity to anti-asparaginase serum. Biochemical and Biophysical Research Communications, 1978; 83: 385.
43. Abuchowski, A. et al., Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase. Cancer Biochemistry and Biophysics, 1984; 7: 175.
44. Kodera, Y. et al., Stabilization of L-asparaginase modified with comb-shaped poly(ethylene glycol) derivatives, in vivo and in vitro. Bioconjugate Chemistry, 1994; 5: 283.
45. Pyatac, P., Abuchowski, A., and Davis, F. F., Preparation of a polyethylene glycol: superoxide dismutase adduct, and examination of its blood circulating life and anti-inflammatory activity. Research Communications in Chemical Pathology and Pharmacology, 1980; 29: 113.
46. Beauchamp, C. O. et al., A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Analytical Biochemistry, 1983; 131: 25.
47. Veronese, F. M. et al., Anti-inflammatory and pharmacokinetic properties of superoxide dismutase derivatized with polyethylene glycol via active esters. Journal of Pharmaceutics and Pharmacology, 1983; 35: 281.
48. Nucci, M. L., Loejarczyk, J., and Abuchowski, A., Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalase. Journal of Free Radical Biology and Medicine, 1986; 2: 321.
49. Beckman, J. S. et al., Superoxide dismutase and catalase conjugated to polyethylene glycol increase endothelial enzyme activity and oxidant resistance. Journal of Biological Chemistry, 1988; 236: 6884.
50. Oural, R. et al., Clinical pharmacokinetics of PEG-superoxide dismutase. Clinical Pharmacology and Therapy, 1988; 43: 136.
51. Tamura, Y. et al., Superoxide dismutase conjugated to polyethylene glycol provides sustained protection against myocardial ischemic/reperfusion injury in the canine heart. Circulation Research, 1988; 63: 944.
52. Inada, Y. et al., Ester synthesis catalyzed by polyethylene glycol-modified lipase in benzene. Biochemical and Biophysical Research Communications, 1984; 122: 845.
53. Takahashi, K. et al., Ester-exchange catalyzed by lipase modified with polyethylene glycol. Biochemical and Biophysical Research Communications, 1985; 131: 532.
54. Kynclova, E. et al., Novel method for coupling of poly(ethyleneglycol) to carboxylic acid moieties of proteins. Journal of Molecular Recognition, 1996; 9: 644.
55. Pizzo, S. V., Preparation, in vivo properties and proposed use of polyoxyethy-lene-modified tissue plasminogen activator and streptokinase. Advanced Drug Delivery Reviews, 1991; 6: 153.
56. Walsh, S., Shah, A., and Mond, J., Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrobial Agents and Chemotherapy, 2003; 47: 554.
57. Woghiren, C., Sharma, B., and Stein, S., Protected thiol-polyethylene glycol: a new activated polymer for reversible protein modification. Bioconjugate Chemistry, 1993; 4: 314.
58. Rajagopalan, S., Gonias, S. L., and Pizzo, S. V., A nonantigenic streptokinasepolyethylene glycol complex with plasminogen activator function. Journal of Clinical Investigation, 1985; 75: 413.
59. Fortier, G., and Laliberte, M., Surface modification of horseradish peroxidase with poly(ethylene glycol)s of various molecular masses. Biotechnology and Applied Biochemistry, 1993; 17: 115.
60. Collen, D. et al., Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphlokinase for single-bolus treatment of acute myocardial infarction. Circulation, 2000; 102: 1766.
61. Caliceti, P. et al., Effects of monomethoxypoly (ethyleneglycol) modification of ribonuclease on antibody recognition, substrate accessibility, and conformational stability. Journal of Molecular Recognition, 1990; 3: 89.
62. Tanaka, H. et al., Pharmacokinetics of recombinant granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Research, 1991; 51: 3710.
63. Niven, R. W. et al., Pulmonary absorption of polyethylene glycolated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF). Journal of Controlled Release, 1994; 32: 177.
64. Jensen-Pippo, K. E. et al., Enteral bioavailability of human granulocyte stimulating factor conjugated with poly(ethylene glycol). Pharmaceutical Research, 1996; 13: 102.
65. Kinstler, O. B., Brems, D. N., and Lauren, S. L., Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceutical Research, 1996; 13: 996.
66. Kinstler, O. B. et al., N-terminally chemically modified protein compositions and methods. US Patent 5,985,265, 1999.
67. Malik, F. et al., Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity. Experimental Hematology, 1992; 20: 1028.
68. Gaertner, H. F., and Offord, R. E., Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjugate Chemistry, 1996; 7: 38.
69. Sherman, M. R. et al., Conjugation of high-molecular weight poly(ethylene glycol) to cytokines: granulocyte-macrophage colony-stimulating factors as model substrates. In: Harris, J. M., and Zalipsky, S. (eds)., Polyethylene Glycol Chemistry and Biological Applications, American Chemical Society, Washington, D.C., 1997, p. 155.
70. Delgado, C., Francis, G. E., and Fisher, D., Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct of PEG and granulocyte-macrophage colony stimulating factor, US Patent 5,880,255, 1999.
71. Gombotz, W. R., and Petit, D. K., PEGylation: A tool to enhance protein delivery. In: Park, K., and Mrsny, R. J. (eds)., Controlled Drug Delivery: Designing Technologies for the Future, American Chemical Society, Washington, D.C., 2000, p. 110.
72. Fannuchi, M. et al., Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer New England Journal of Medicine, 1997; 336: 404.
73. Eliason, J. F. et al., Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein with high molecular weight polyethylene glycol. Stem Cells, 2000; 18: 40.
74. Farese, A. M. et al., A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells, 2001; 19: 514.
75. Lee, K. C. et al., Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharmaceutical Research, 1999; 16: 813.
76. Clark, R. et al., Long-acting growth hormones produced by conjugation with polyethylene glycol. Journal of Biological Chemistry, 1996; 271: 21969.
77. Geiger, R. et al., Biological activity of insulin analogs substituted at the amino group of B1-phenylalanine. In: Branderburg, D., and Wollmer, A. (eds)., Insulin: Chemistry, Structure, and Function of Insulin and Related Hormones, Walter de Gruyter & Co., New York, 1980, p. 409.
78. Neubauer, H. P., Obermeier, R., and Schone, H. H., Influence of poly(ethylene glycol) insulin on the lipid tissues of experimental animals. Diabetes, 1983; 32: 953.
79. Ehrat, M., and Luisi, P. L., Synthesis and spectroscopic characterization of insulin derivatives containing one or two poly(ethylene glycol) chains at specific positions. Biopolymers, 1983; 22: 569.
80. Caliceti, P., and Veronese, F. M., Successful insulin delivery by PEG conjugation. Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 1998; 25: 263.
81. Caliceti, P., and Veronese, F. M., Improvement of the physicochemical and biopharmaceutical properties of insulin by poly(ethylene glycol) conjugation. S. T. P. Pharma Sciences, 1999; 9: 107.
82. Uchio, T. et al., Novel site-specific insulin conjugates with enhanced stability and extended action profile for parenteral delivery. Advanced Drug Delivery Reviews, 1999; 35: 289.
83. Hinds, K. et al., Synthesis and characterization of poly(ethylene glycol)-insulin conjugates. Bioconjugate Chemistry, 2000; 11: 195.
84. Hinds, K. D., and Kim, S. W., Effects of PEG conjugation on insulin properties. Advanced Drug Delivery Reviews, 2002; 54: 505.
85. Lee, H. et al., N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharmaceutical Research, 2003; 20: 818.
86. Morpurgo, M. et al., Selective alkylation and acylation of α and ε amino groups with PEG in a somatostatin analog: tailored chemistry for optimized bio conjugates. Bioconjugate Chemistry, 2002; 13: 1238.
87. Huber, J. D. et al., Conjugation of low molecular weight poly(ethylene glycol) to biphalin enhances antinociceptive profile. Journal of Pharmaceutical Sciences, 2003; 92: 1377.
88. Felix, A. M., Lu, Y. A., and Campbell, R. M., Pegylated peptides IV: Enhanced biological activity of site-directed pegylated GRF analogs. International Journal of Peptide and Protein Research, 1995; 46: 253.
89. Felix, A. M., Site-specific poly(ethylene glycol)ylation of peptides. In: Harris, J. M., and Zalipsky, S. (eds)., Polyethylene Glycol Chemistry and Biological Applications, American Chemical Society, Washington, D.C., 1997, p. 218.
90. Campbell, R. M. et al., Pegylated peptides V: Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo. Journal of Peptide Research, 1997; 49: 527.
91. Ross, R. J. M. et al., Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (Pegvisomant). reveal effects of Pegylation and evidence that it binds to a receptor dimer. Journal of Clinical Endocrinology and Metabolism, 2001; 86: 1716.
92. Belcheva, N. et al., Synthesis and biological activity of polyethylene glycol-mouse nerve growth factor conjugate. Bioconjugate Chemistry, 1999; 10: 932.
93. Na, D. H. et al., Preparation and stability of PEGylated octreotide for application to microsphere. In: AAPS Annual Meeting and Exposition, Salt Lake City, UT, 2003.
94. Monkarsh, S. P. et al., Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Analytical Biochemistry, 1997; 247: 434.
95. Monkarsh, S. P. et al., Isolation of positional isomers of mono-poly(ethylene glycol)ylated interferon/a-2a and the determination of their biochemical and biological characteristics. In: Harris, J. M., and Zalipsky, S. (eds)., Polyethylene Glycol Chemistry and Biological Applications, American Chemical Society, Washington, D.C. 1997, p. 207.
96. Wang, Y. S. et al., Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry, 2000; 39: 10634.
97. Bailon, P. et al., Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon a-2a for the treatment of hepatitis C. Bioconjugate Chemistry, 2001; 12: 195.
98. El Tayar, N. et al., Polyol-IFN-Beta Conjugates, WO 99/55377, 1999.
99. Pepinsky, R. B. et al., Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. The Journal of Pharmacology and Experimental Therapeutics, 2001; 297: 1059.
100. Tsunoda, S. et al., Enhanced antitumor potency of polyethylene glycolated tumor necrosis factor-a: A novel polymer-conjugation technique with a reversible amino-protective reagent. The Journal of Pharmacology and Experimental Therapeutics, 1999; 290: 368.
101. Li, Y.-P. et al., PEGylated recombinant human tumor necrosis factor alpha: Pharmacokinetics and anti-tumor effects Biological and Pharmacological Bulletin, 2001; 24: 66.
102. Katre, N. V., Knauf, M. J., and Laird, W. J., Chemical modification of recombinant interleuken 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proceedings of the National Academy of Sciences USA, 1987; 84: 1487.
103. Katre, N. V., Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. Journal of Immunology, 1990; 144: 209.
104. Knauf, M. J. et al., Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water soluble polymers. The Journal of Biological Chemistry, 1988; 263: 15064.
105. Chen, S. A. et al., Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs. The Journal of Pharmacology and Experimental Therapeutics, 2000; 293: 248.
106. Tsutsumi, Y. et al., PEGylation of interleukin-6 effectively increases its thrompoetic potency, Thrombosis and Haemostasis. 1997; 77: 168.
107. Tsunoda, S. et al., Selective enhancement of thrombopoetic activity of PEGylated interleukin-6 by a simple procedure using a reversible amino-protective reagent. British Journal of Haematology, 2001; 112: 181.
108. Petit, D. K. et al., Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation and homology modeling. Journal of Biological Chemistry, 1997; 272: 2312.
109. Cunningham-Rundles, C. et al., Biological activities of polyethylene-glycol immunoglobulin conjugates. Journal of Immunological Methods, 1992; 152: 177.
110. Suzuki, T. et al., Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G. Biochimica et Biophysica Acta, 1984; 788: 248.
111. Wilkinson, I. et al., Tolerogenic polyethylene glycol derivatives of xenogenic monoclonal immunoglobulins. Immunology Letters, 1987; 15: 17.
112. Eno-Amooquaye, E. A. et al., Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol. British Journal of Cancer, 1996; 73: 1323.
113. 0 fragment by poly(ethlyene glycol) (PEG) modification. British Journal of Cancer, 1996; 73: 175.
114. Leong, S. R. et al., Adapting pharmacokinetic properties of a humanized antiinterleukin-8 antibody for therapeutic applications using site-specific PEGyla-tion. Cytokines, 2001; 16: 106.
115. 0)2 by anime-specific PEGylation with preserved bioactivity. International Journal of Pharmaceutics, 2000; 198: 83.
116. Lee, L. S., et al., Prolonged circulating lives of single-chain FV proteins conjugated with polyethylene glycol: A comparison of conjugation chemistries and compounds. Bioconjugate Chemistry, 1999; 10: 973.
117. Green, M. E. et al., Site-specific modification of a mutant cyanovirin-N with a large polyethylene glycol moiety yields a potent anti-HIV agent with reduced immunogenicity and toxicity in mice. 30th Annual Meeting of the Controlled Release Society, Glasgow, UK, 2003.
118. Wu, D., and Partridge, W. M., Neuroprotection with noninvasive neurotrophin delivery to the brain. Proceedings of the National Academy of Sciences USA, 1999; 96: 254.
119. Edwards, C. K., 3rd, PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic rheumatoid arthritis. Annals of the Rheumatic Diseases, 1999; 58: 173.
120. Kerwin, B. A. et al., Interactions between PEG and type I soluble tumor necrosis factor receptor: Modulation by pH and by PEGylation at the N terminus. Protein Science, 2002; 11: 1825.
121. Ajisaka, K., and Iwashita, Y., Modification of human haemoglobin with polyethylene glycol: a new candidate for blood substitute. Biochemical and Biophysical Research Communications, 1980; 97: 1076.
122. Leonard, M. J. N., and Dellacherie, E., Synthesis of monomethoxypolyox-yethylene-bound hemoglobins. Tetrahedron, 1984; 40: 1581.
123. Leonard, M., and Dellacherie, E., Acylation of human hemoglobin with polyoxyethylene derivatives. Biochimica et Biophysica Acta, 1984; 791: 219.
124. Iwasaki, K., and Iwashita, Y., Preparation and evaluation of hemoglobin-polyethylene glycol conjugate (pyridoxylated polyethylene glycol hemoglobin) as an oxygen carrying resuscitation fluid. Artificial Organs, 1986; 10: 411.
125. Greenwald, R. B. et al., PEG thiazolidine-2-thione, a novel reagent for facile modification: Conjugation of bovine hemoglobin. Bioconjugate Chemistry, 1996; 7: 638.
126. Bossavy, J. P. et al., Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Arteriosclerosis and Thrombosis Vascular Biology, 1999; 19: 1348.
127. Lee, W. Y., Sehon, A. H., and Akerblom, E., Suppression of reaginic antibodies with modified allergens. IV. Induction of suppressor T cells by conjugates of polyethylene glycol (PEG) and monomethoxy PEG with ovalbumin. International Archives of Allergy and Applied Immunology, 1981; 64: 100.
128. Jackson, C.-J. C. et al., Synthesis, isolation, and characterization of conjugates of ovalbumin with monomethoxypolyethylene glycol using cyanuric chloride as the coupling agent. Analytical Biochemistry, 1987; 165: 114.
129. Nakhgevany, R. et al., Preparation, purification, and spectrophotometric characterization of cytochrome P450 1A2 conjugated with polyethylene glycol monomethyl ether. Biochemical and Biophysical Research Communications, 1996; 222: 406.
130. Rhee, W. et al., Bovine Collagen modified by Pe.g. In: Harris, J. M. (ed.), Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, Plenum Press, New York, 1992, p. 183.
131. Floege, J. et al., Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers American Journal of Pathology, 1999; 154: 169.
132. O’Riordan, C. R. et al., PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Human Gene Therapy, 1999; 10 1349.
133. Alemany, R., Suzuki, K., and Curiel, D. T., Blood clearance of adenovirus type 5 in mice. Journal of General Virology, 2000; 81: 2605.
134. Croyle, M. A. et al., "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. Journal of Virology, 2001; 75: 4792.
135. Caliceti, P., and Veronese, F. M., Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Advanced Drug Delivery Reviews, 2003; 55: 1261.
136. Wong, S. S., Reactive groups of proteins and their modifying agents. Chemistry of Protein Conjugation and Cross-Linking, CRC Press, Boca Raton, 1991, p.7.
137. Suhr, H., Effect of leaving group on the velocity of nucleophilic aromatic substitutions. Berichte, 1964; 97: 3268.
138. Bunnett, J. F., Nucleophilic reactivity. Annual Reviews in Physical Chemistry, 1963; 14: 271.
139. Greenwald, R. B. et al., Effective drug delivery by PEGylated drug conjugates. Advanced Drug Delivery Reviews, 2003; 55: 217.
140. Dust, J. M., Fang, Z.-H., and Harris, J. M., Proton NMR characterization of poly(ethylene glycols) and derivatives. Macromolecules, 1990; 23: 3742.
141. Matsushima, A. et al., Modification of E. coli asparaginase with 2,4-bis (o-methoxypolyethylene glycol)-6-chloro-s-trazine (activated PEG2); disappearance of binding ability towards anti-serum and retention of activity. Chemical Letters, 1980; 773.
142. Yamasaki, N., Matsuo, A., and Isobe, H., Novel polyethylene glycol derivatives for modification of proteins. Agricultural and Biological Chemistry, 1988; 52: 2125.
143. Veronese, F. M. et al., Improved pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched mono-methoxypoly (ethylene glycol). Journal of Controlled Release, 1996; 40: 199.
144. Harris, J. M., and Kozlowski, A., Polyethylene glycol derivatives with proximal reactive groups. WO 99/45964, 1999.
145. Nathan, A. et al., Hydrogels based on water-soluble poly(ether urethanes) derived from L-lysine and Pe.g. Macromolecules, 1992; 25: 4476.
146. Davis, F. F., van Es, T., and Palczuk, N. C., Non-immunogenic polypeptides, US Patent 4,179,337, 1979.
147. Pollak, A., and Whitesides, G. M., Organic synthesis using enzymes in two-phase aqueous ternary polymer systems. Journal of the American Chemical Society, 1976; 98: 289.
148. Zalipsky, S., Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates, Bioconjugate Chemistry, 1995; 6: 150.
149. Zalipsky, S., Gilon, C., and Zilkha, A., Attachment of drugs to polyethylene glycols. European Polymer Journal, 1983; 19: 1177.
150. Zalipsky, S., and Monon-Rudolph, S., Hydrazide derivatives of poly(ethylene glycol) and their bioconjugates. In: Harris, J. M., and Zalipsky, S. (eds)., Polyethylene Glycol Chemistry and Biological Applications. American Chemical Society, Washington, D.C., 1997, p.318.
151. Tondelli, L. et al., Poly(ethylene glycol) imidazolyl formate as oligomeric drug-binding matricies. Journal of Controlled Release, 1985; 1: 251.
152. Ranucci, E., and Ferrati, P., Block copolymers containing poly(ethylene glycol) and poly(amido-amine) or poly(amino-thioether-amine) segments. Macromolecules, 1991; 24: 374.
153. Veronese, F. M. et al., Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase. Applied Biochemistry and Biotechnology, 1985; 11: 141.
154. Zalipsky, S., Seltzer, R., and Menon-Rudolph, S., Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. Biotechnology and Applied Biochemistry, 1992; 15: 100.
155. Dolence, E. K. et al., Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces. US Patent 5,650,234, 1997.
156. Orsatti, L., and Veronese, F. M., An unusual coupling of poly(ethylene glycol) to tyrosine residues in epidermal growth factor. Journal of Bioactive and Compatible Polymers, 1999; 14: 429.
157. Zalipsky, S. et al., A convenient general method for synthesis of N alpha- and N omega-dithiasuccinoyl (Dts) amino acids and dipeptides: application of polyethylene glycol as a carrier for functional purification. International Journal of Peptide and Protein Research, 1987; 30: 740.
158. King, T. P., and Weiner, C., Preparation of protein conjugates with alkoxy-polyethylene glycols. International Journal of Peptide and Protein Research, 1980; 16: 147.
159. Greenwald, R. B., Pendri, A., and Bolikal, D., Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates. Journal of Organic Chemistry, 1995; 60: 331.
160. Buckmann, A., Morr, M., and Johansson, G., Functionalization of polyethylene glycol and monomethoxy-polyethylene glycol. Makromolecular Chemistry, 1981; 182: 1379.
161. Nilsson, K., and Mosbach, K., Immobilization of ligands with organic sulfonyl chlorides. Methods in Enzymology, 1984; 104: 56.
162. Bohlen, P. et al., Fluorometric assay of proteins in the nanogram range. Archives in Biochemistry and Biophysics, 1973; 155: 213.
163. Stocks, S. J. et al., A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol. Analytical Biochemistry, 1986; 154: 232.
164. Ueno, H., and Fujino, M., Production of chemically modified proteins. US Patent 5,109,120, 1987.
165. Elling, L., and Kula, M.-R., Immunoaffinity partitioning: synthesis and use of polyethylene glycol-oxirane for coupling to BSA and monoclonal antibodies. Biotechnology and Applied Biochemistry, 1991; 13: 354.
166. Harris, J. M., and Herati, R. M., Preparation and use of polyethylene glycol propionaldehyde. US Patent 5 252,714, 1993.
167. Goodson, R. J., and Katre, N. V., Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Bio/Technology, 1990; 8: 343.
168. Kogan, T. P., The synthesis of substituted methoxypoly(ethylene glycol) derivatives suitable for selective protein modification. Synthetic Communications, 1992; 22: 2417.
169. Ishi, Y., and Lehrer, S. S., Effects of the state of the succinimido-ring on the fluorescence and structural properties of pyrene maleimide-labeled alpha alphatropomyosin. Biophysical Journal, 1986; 50: 75.
170. Morpurgo, M. et al., Preparation and characterization of poly(ethylene glycol) vinyl sulfone. Bioconjugate Chemistry, 1996; 7: 363.
171. Mutter, M., and Bayer, E., Special methods in peptide synthesis, part A. In: Gross, E., and Meienhofer, J. (eds)., The Peptides, Vol. 2, Academic Press, New York, 1979, p.285.
172. Ferruti, P. et al., Succinic half-esters of poly(ethylene glycol)s and their benzotriazole and imidazole derivatives as oligomeric drug-binding matricies. Makromolecular Chemistry, 1981; 182: 2183.
173. Sheffield, W. P., Modification of the clearance of therapeutic and potentially therapeutic proteins. Current Drug Targets in Cardiovascular and Hematological Disorders, 2002; 1: 1.
174. Choi, S. H., Lee, H., and Park, T. G., PEGylation of G-CSF using cleavable oligo-lactic acid linkage. Journal of Controlled Release, 2003; 89: 271.
175. Garman, A. J., and Kalindijan, S. B., The preparation and properties of novel reversible polymer-protein conjugates, FEBS Letters, 1987; 223: 361.
176. Zhao, X., and Bentley, M. D., A hydrolyzable linkage for PEG-proteins. Ninth International Symposium of Recent Advances in Drug Delivery Systems, Salt Lake City, UT, 1999.
177. Lee, S. et al., Drug delivery systems employing 1,6-elimination: Releasable poly(ethylene glycol) conjugates of proteins. Bioconjugate Chemistry, 2001; 12: 163.
178. Zalipsky, S. et al., New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidy-lethanolamine. Bioconjugate Chemistry, 1999; 10: 703.
179. Zalipsky, S., and Barany, G., Preparation of polyethylene glycol derivatives with two different functional groups at the termini Polymer Preprints, American Chemical Society Division of Polymer Chemistry, 1986; 27: 1.
180. Bentley, M. D., Harris, J. M., and Kozlowski, A., Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation, WO 126692A1, 2001.
181. Yokoyama, M. et al., Synthesis of poly(ethylene oxide) with heterobifunctional reactive groups at is terminals by an anionic initiator. Bioconjugate Chemistry, 1992; 3: 275.
182. Nagasaki, Y. et al., Formyl-ended heterobifunctional poly(ethylene oxide): synthesis of poly(ethylene oxide) with a formyl group at one end and a hydroxyl groups at the other end. Bioconjugate Chemistry, 1995; 6: 231.
183. Lee, H., and Park, T. G., Preparation and characterization of mono-PEGylated epidermal growth factor: Evaluation of in vitro biologic activity. Pharmaceutical Research, 2002; 19: 845.
184. Leach, C. et al., PEG-insulin delivered by the pulmonary route provides prolonged systemic activity compared with insulin alone. AAPS Meeting and Exposition, Toronto, Canada, 2002.
185. Rajender Reddy, K., Modi, M. W., and Pedder, S., Use of peginterferon alfa-2a (40KD) (Pegasys) for the treatment of hepatitis C, Advanced Drug Delivery Reviews, 2002; 54: 571.
186. Kinstler, O. et al., Mono-N-terminal poly(ethylene glycol)-protein conjugates, Advanced Drug Delivery Reviews, 2002; 54: 477.
187. Leung, S.-O. et al., Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments. Journal of Immunology, 1995; 154: 5919.
188. Chapman, A. P. et al., Therapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnology, 1999; 17: 780.
189. Wang, Q.-C. et al., Polyethylene glycol-modified chimeric toxin composed of transforming growth factor a and Pseudomonas exotoxin. Cancer Research, 1993; 53: 4588.
190. Hershfield, M. S. et al., Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proceedings of the National Academy of Sciences USA, 1991; 88: 7185.
191. Liu, F. et al., Bioactive polyethylene glycol-insulin conjugates with enhanced stability. Polymer Preprints, 1997; 38: 595.
192. Petit, D. K. et al., Site protected PEGylation of recombinant tumor necrosis factor receptor. ACS National Spring Meeting, San Francisco, CA, 1997.
193. Sato, H., Enzymatic procedure for site-specific pegylation of proteins. Advanced Drug Delivery Reviews, 2002; 54: 487.
194. Diwan, M., and Park, T. G., Stabilization of interferon-alpha by pegylation for encapsulation in PLGA microspheres. International Journal of Pharmaceutics, 2003; 252: 111.
195. Hinds, K. D., Unpublished data, 2002.
196. AP Biotech, Ion Exchange Chromatography: Principals and Methods, Uppsala, Sweden, 1999.
197. Seeley, J. E., and Richey, C. W., Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. Journal of Chromatography A, 2001; 908: 235.
198. Hjerten, S., Some general aspects of hydrophobic interaction chromatography. Journal of Chromatography, 1973; 87: 325.
199. Snider, J. et al., Characterization of the heterogeneity of polyethylene glycol-modified superoxide dismutase by chromatographic and electrophoretic techniques, Journal of Chromatography, 1992; 599: 141.
200. Cunico, R. L. et al., Characterization of polyethylene glycol modified proteins using charge-reversed capillary electrophoresis. Journal of Chromatography, 1991; 559: 467.
201. Veronese, F. M., Peptide and protein PEGylation: a review of problems and solutions. Biomaterials, 2001; 22: 405.
202. Sims, G. E. C., and Snape, T. J., A method for the estimation of polyethylene glycol in plasma protein fraction. Analytical Biochemistry, 1980; 107: 60.
203. Nag, A., Mitra, G., and Ghosh, P. C., A colorimetric assay for estimation of polyethylene glycol and polyethylene glycolated protein using ammonium ferrothiocyanate. Analytical Biochemistry, 1996; 237: 224.
204. Habeeb, A. F. S. A., Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Analytical Biochemistry, 1966; 14: 328.
205. Riddles, P. W., Blakely, R. L., and Zerner, B., Ellman’s reagent: 5,5'-dithiobis (2-nitrobenzoic acid)- a reexamination. Analytical Biochemistry, 1979; 94: 75.
206. Creighton, T. E. (ed)., Protein Structure: a Practical Approach. IRL Press, Oxford, 1990, p. 155.
207. Sartore, L. et al., Accurate evaluation method of the polymer content in monomethoxypoly(ethylene glycol) modified proteins based on amino acid analysis. Applied Biochemistry and Biotechnology, 1991; 31: 213.
208. Delgado, C. et al., Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnology and Applied Biochemistry, 1990; 12: 119.
209. Roberts, M. J., and Harris, J. M., Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. Journal of Pharmaceutical Sciences, 1998; 87: 1440.
210. Zhao, Z., Malik, A., and Lee, M. L., Solute adsorption on polymer-coated fused-silica capillary electrophoresis columns using selected protein and peptide standards. Analytical Chemistry, 1993; 65: 2474.
211. Preisler, J., and Yeung, E. S., Characterization of nonbonded poly(ethylene oxide) coatings for capillary electrophoresis via continuous monitoring of electroosmotic flow. Analytical Chemistry, 1996; 68: 2885.
212. Esaka, Y. et al., Separation of hydrogen-bonded donors in capillary electrophoresis using polyethers as matrix. Analytical Chemistry, 1994; 66: 2441.
213. Iki, N., and Yeung, E. S., Nonbonded poly(ethylene oxide) polymer-coated column for protein separation by capillary electrophoresis. Journal of Chromatography A, 1996; 731: 273.
214. Bullock, J., Chowdhury, S., and Johnston, D., Characterization of poly(-ethylene glycol)-modified superoxide dismutase: Comparison of capillary electrophoresis and matrix-assisted laser desorption/ionization mass spectrometry. Analytical Chemistry, 1996; 68: 3258.
215. Wang, J.-L. et al., Polyethylene glycolated recombinant TNF receptor I improves and reduces incidence of spontaneous and cyclophosphamide-accelerated diabetes in nonobese diabetic mice. Endocrinology, 2002; 143: 349.
216. Wang, Y.-S. et al., Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Advanced Drug Delivery Reviews, V; 54: 547.
217. Delgado, C., Francis, G. E., and Fisher, D., The uses and properties of PEG-linked proteins. Critical Reviews in Therapeutic Drug Carrier Systems, 1992; 9: 249.
218. Kunitani, M. et al., On-line characterization of polyethylene glycol-modified proteins. Journal of Chromatography, 1991; 588: 125.
219. Kendrick, B. S. et al., Online size-exclusion high-performance liquid chromatography light scattering and differential refractometry methods to determine degree of polymer conjugation to proteins and protein-protein or protein-ligand association states. Analytical Biochemistry, 2001; 299: 136.
220. Yamasaki, M. et al., Modification of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and its derivative ND 28 with polyethylene glycol. Journal of Biochemistry, 1994; 115: 814.
221. Yoshinaga, K., et al. PEG-modified protein hybrid catalyst. In: Harris, J. M. (ed.), Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications. Plenum Press, New York, 1992, p. 103.
222. Bloemendal, M., and Johnson, W. C. Jr., Structural information on proteins from circular dichroism spectroscopy possibilities and limitations. In: Herron, J. N. et al. (eds)., Physical Methods to Characterize Pharmaceutical Proteins, Plenum Press, New York, 1995, p. 65.
223. Bohm, G., Muhr, R., and Jaenicke, R., Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Engineering, 1992; 5: 191.
224. Sharp, K. A. et al., Synthesis and application of a poly(ethylene glycol)-antibody affinity ligand for cell separations in aqueous polymer two-phase systems. Analytical Biochemistry, 1986; 154: 110.
225. Chen, D. et al., Detecting PEG-rHu MGDF in rhesus monkey serum: An enzyme-linked immunosorbent assay. BioPharm, 2000; April:, 48.
226. Collen, D. et al., Recombinant staphylokinase variants with altered immunor-eactivity, II: thrombolytic properties and antibody induction. Circulation, 1996; 94: 204.
227. Miller, K. J., and Herman, A. C., Affinity chromatography with immunochemical detection applied to the analysis of human methionyl granulocyte stimulating factor in serum. Analytical Chemistry, 1996; 68: 3077.
228. Tsai, N.-M., Cheng, T.-L., and Roffler, S. R., Sensitive measurement of polyethylene glycol-modified proteins. BioTechniques, 2001; 30: 396.
229. Nucci, M. L., and Abuchowski, A., The therapeutic value of poly(ethylene glycol)-modified proteins. Advanced Drug Delivery Reviews, 1991; 6: 133.